Narrow search
Showing 1 - 10 of 728
Cover Image
Improving data on pharmaceutical expenditure in hospitals and other health care settings
Morgan, David - 2022
As a key component of health care, a full understanding of how much is spent on prescription medicines is increasingly important. Only a partial understanding of total expenditures across health systems is currently possible, as reporting is often limited to medicines dispensed in community...
Persistent link: https://www.econbiz.de/10013202471
Cover Image
An Unnecessary Proposal : A WTO Waiver of Intellectual Property Rights for COVID-19 Vaccines
Baachus, James - 2021
In a sign of their increasing frustration with global efforts to ensure that all people everywhere will have access to COVID-19 vaccines, several developing countries have asked other members of the World Trade Organization (WTO) to join them in a sweeping waiver of the intellectual property...
Persistent link: https://www.econbiz.de/10013248992
Cover Image
An Ounce of Prevention or a Pound of Cure? Short- and Long-Run Effects of Pharmaceutical Patents on U.S. Health Care Expenditures
Johnson, Hilary S.; Johnson, Daniel K. N. - 2014
This study examines the relationship between pharmaceutical R&D and health care expenditures, distinguishing between the short- and long-run impacts. To measure these relationships quantitatively, we focus on patents as a key factor driving the costs of pharmaceuticals, and develop a structured...
Persistent link: https://www.econbiz.de/10014209235
Cover Image
Biologic Drugs, Biosimilars, and Barriers to Entry
Shepherd, Joanna - 2014
Biologic drugs represent an important category of drugs that improve health outcomes in this country. Yet, these cutting-edge drugs are often prohibitively costly, preventing access for many Americans. Recognizing the need for more affordable, generic substitutes for biologic drugs — or...
Persistent link: https://www.econbiz.de/10014148056
Cover Image
Canada's Patented Medicines (Notice of Compliance) Regulations : Removing Inefficiencies to Encourage Generic Competition
Porter, Suzanne - 2013
Canada's Patented Medicines (Notice Of Compliance) Regulations fail to achieve the intended purpose of balancing innovation with timely generic market entry. An examination of the inefficiencies created by the Canadian regulations reveals that key features of U.S. pharmaceutical law should be...
Persistent link: https://www.econbiz.de/10013074086
Cover Image
Biosimilars inthe French and Polish system : chosen aspects of reimbursement and access
Barszczewska, Olga; Chami, Ralph; Piechota, Anna - In: Comparative economic research : Central and Eastern Europe 23 (2020) 2, pp. 103-115
unique reimbursement system, which results in significant differences in patients’ access to biosimilars. The importance of …. The aim of this paper is to compare selected aspects of reimbursement and access to the EMA authorized biosimilar … database, the Polish reimbursement list published by the Polish Ministry of Health, and two French reimbursement databases …
Persistent link: https://www.econbiz.de/10012417671
Cover Image
Provision of Pharmaceuticals in Russia : Current Situation and Prospects for the Future
Avksentiev, Nikolay - 2019
An analysis of the consumption of prescription pharmaceuticals and the structure of pharmaceutical care costs has demonstrated that the availability of pharmaceuticals is still low, and that households have to pay for more than half of those costs. It has also been revealed that availability of...
Persistent link: https://www.econbiz.de/10012859587
Cover Image
Product patents and access to innovative medicines in a post-trips-era
Watal, Jayashree; Dai, Rong - 2019 - Manuscript date: 28 March 2019
This WTO working paper studies availability and affordability of new and innovative pharmaceuticals in a post-TRIPS era. The WTO's TRIPS Agreement (TRIPS) makes it obligatory for WTO members − except least-developed country members (LDCs) - to provide pharmaceutical product patents with a...
Persistent link: https://www.econbiz.de/10011992779
Cover Image
Demand Side Cost-Sharing and Prescription Drugs Utilization : Evidence from a Quasi-Natural Experiment
Hromadkova, Eva; Zdenek, Michal - 2013
In this paper we investigate the effects of introduction of lump sum copayments on the utilization of prescription drugs by elderly patients. We make use of an unique dataset and analyze the policy change that implemented patient cost-sharing in the Czech Republic starting in 2008. After the...
Persistent link: https://www.econbiz.de/10014158324
Cover Image
Product Patents and Access to Innovative Medicines in a Post TRIPS Era
Watal, Jayashree; DAI, Rong - 2019
This paper examines access to new and innovative pharmaceuticals in a post-TRIPS era. The WTO’s TRIPS Agreement (TRIPS) makes it obligatory for WTO members – except least-developed country members (LDCs) - to provide pharmaceutical product patents with a 20-year protection term. Developing...
Persistent link: https://www.econbiz.de/10014105991